Instructions for Use — Patient Labeling for Human Prescription Drug and Biological

14 July 2022 — FDA published the final guidance for industry.

This guidance provides recommendations for developing the content and format of a patient Instructions for Use (IFU) document for human prescription drug and biological products, as well as drug-led or biologic-led combination products submitted under a new drug application (NDA) or a biologics license application (BLA).

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /